Erasca reported favorable safety and tolerability with no dose-limiting toxicities and predominantly low-grade adverse events across all dose levels. Initial Phase 1 monotherapy data for ERAS-0015 are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback